An open-label, non-randomized, multicenter effectiveness, safety and tolerability study of oxymorphone HCL immediate-release oral liquid in opioid-tolerant pediatric subjects with chronic pain requiring an around the clock opioid.

Trial Profile

An open-label, non-randomized, multicenter effectiveness, safety and tolerability study of oxymorphone HCL immediate-release oral liquid in opioid-tolerant pediatric subjects with chronic pain requiring an around the clock opioid.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2012

At a glance

  • Drugs Oxymorphone (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 29 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top